论文部分内容阅读
目的探讨脑心通联合依达拉奉治疗脑梗死患者的临床疗效。方法选择2013年4月至2014年4月株洲市三三一医院接受诊治的急性脑梗死患者103例,按照入院就诊顺序分为治疗组54例和对照组49例。治疗组采用脑心通联合依达拉奉治疗,对照组单用依达拉奉治疗。两组患者均以7 d为1个疗程,连续治疗2个疗程,比较两组疗效。结果治疗组总有效率(90.74%)明显高于对照组(75.51%),差异有统计学意义(P<0.05);两组治疗后神经功能缺血(NIHSS)评分明显低于治疗前,差异有统计学意义(P<0.05);治疗组治疗后NIHSS评分明显低于对照组,差异有统计学意义(P<0.05);两组治疗后日常生活能力(ADL)评分明显高于治疗前,差异有统计学意义(P<0.05);治疗组治疗后ADL评分明显高于对照组,差异有统计学意义(P<0.05);两组治疗后血清S-100β、神经元特异性烯醇酶(NSE)水平明显低于治疗前,差异有统计学意义(P<0.05);观察组治疗后血清S-100β、NSE水平明显低于对照组,差异有统计学意义(P<0.05)。两组治疗期间均未发生不良反应。结论脑心通联合依达拉奉治疗脑梗死患者临床疗效显著,具有重要研究意义。
Objective To investigate the clinical effects of Naoxintong combined with edaravone in patients with cerebral infarction. Methods From April 2013 to April 2014, 103 patients with acute cerebral infarction undergoing diagnosis and treatment in Trinity Hospital of Zhuzhou City were divided into treatment group (n = 54) and control group (n = 49) according to the order of admission. The treatment group was treated with Naoxintong combined with edaravone and the control group with edaravone alone. Two groups of patients were 7 d for a course of treatment for two courses of continuous treatment, the two groups were compared. Results The total effective rate (90.74%) in the treatment group was significantly higher than that in the control group (75.51%), the difference was statistically significant (P <0.05); NIHSS score was significantly lower in both groups after treatment than before treatment (P <0.05). NIHSS score of the treatment group was significantly lower than that of the control group after treatment (P <0.05), ADL score of the two groups was significantly higher than that before treatment (P <0.05). After treatment, the ADL score of the treatment group was significantly higher than that of the control group (P <0.05). After treatment, the levels of S-100β, neuron-specific enolase (NSE) was significantly lower than that before treatment (P <0.05). The levels of serum S-100β and NSE in the observation group were significantly lower than those in the control group (P <0.05). No adverse reactions occurred in both groups during the treatment. Conclusion Naoxintong combined edaravone treatment of patients with cerebral infarction significant clinical effect, has important research significance.